The phrase "personalised medicine" has been adopted by oncology, genomics, and pharmaceutical research to describe treatments tailored to the specific molecular profile of a tumour or a patient's genetic variants. It is considered the frontier of medical science. Large institutions fund it. Prestigious journals publish it. The BMJ and NEJM run features on its promise.
And yet when a private functional medicine practitioner in Edinburgh applies the same underlying principle — that your biology is specific to you, that your test results need to be interpreted in the context of your history, your medications, your stress load, your digestive function, and your genetics, and that the intervention needs to match the individual rather than the diagnostic category — the same clinical logic is frequently positioned as fringe, anecdotal, or "not evidence-based."
The double standard is worth examining. Not because functional medicine is beyond criticism — it is not, and its evidence base varies considerably by clinical application — but because the principle of individual-specific assessment and intervention is not controversial in academic medicine. It is the direction academic medicine is explicitly moving. The controversy is about who is doing it, and for whom, and at what price point.
What One-Size-Fits-All Actually Means
The conventional healthcare model is not designed to fail individuals. It is designed to do the maximum good for the maximum number of people within a finite resource constraint. This is a legitimate and genuinely difficult design challenge, and the NHS solves it with remarkable consistency given the scale at which it operates.
But the design choices required to serve populations at scale produce systematic gaps when applied to individuals. Reference ranges are set at population level — identifying disease, not optimising function. Treatment protocols are based on average responses in clinical trials — which, by definition, represent the middle of a distribution. Drug dosing is standardised — despite the pharmacogenomic reality that CYP450 enzyme variants cause the same dose to produce dramatically different blood levels and effects in different people. Dietary guidance is population-level — despite the well-established reality that metabolic response to the same meal varies by a factor of ten between individuals, as the Weizmann Institute's continuous glucose monitoring studies demonstrated clearly in 2015.
The system produces average outcomes for average patients. The person who sits in the middle of the distribution — whose physiology roughly matches the population average — tends to do reasonably well. The person whose biology diverges significantly from the average — in their metabolic type, their genetic variants, their gut microbiome composition, their stress response, their medication burden — tends to cycle through the system without resolution, accumulating diagnoses that describe their symptoms without explaining them.
"Standard medicine was designed for populations. Personalised medicine is designed for the individual sitting in front of you. These are different problems requiring different tools — and the tools for individual-specific assessment now exist outside the NHS waiting list."
The Structural Reasons It Cannot Change Quickly
There is a pattern in how large healthcare systems respond to individual-specific assessment. The concept is embraced at the research level — precision oncology, pharmacogenomics, microbiome-guided treatment — and simultaneously resisted at the point of clinical delivery, where the economic and logistical constraints of scale make it practically impossible to implement.
A GP appointment is currently averaging around 12 minutes in the UK. In that time, a clinician is expected to take a history, examine the patient, make an assessment, initiate investigations or treatment, and document the consultation. Personalised assessment — reading the intersection of someone's metabolic type, medication burden, nutrient status, gut function, hormone profile, and stress physiology — requires time, data, and clinical pattern recognition that 12 minutes cannot accommodate. This is not a criticism of GPs, who are operating within structural constraints they did not design and cannot individually change. It is an observation about what the structure makes possible.
The pharmaceutical model compounds this. Drug development operates on population-level efficacy — a drug must demonstrate statistically significant benefit compared to placebo across a trial population to achieve approval. Individual response variation is averaged out in the analysis. The drug that produces excellent outcomes in 60% of patients and no benefit or harm in 40% passes regulatory review. The 40% who receive no benefit are invisible in the aggregate data, and there is no clinical infrastructure to identify them in advance.
Bill Wolcott’s Metabolic Typing system — drawing on Weston Price, Francis Pottenger and Roger Williams — put a name to something I see every week: the same meal suits one person and leaves another flat. Biochemical individuality is real. Roger Williams, a mainstream biochemist at the University of Texas, documented how much people differ in the 1950s.
What hasn’t held up is the specific system. No trial has shown that typing people as fast or slow oxidisers and feeding them accordingly improves outcomes. I trained in it, used it for years, and wrote about why I stopped treating it as a rule. Metabolic Natures is what I use now: a starting point, checked against how you actually respond. Personalising care is a good idea; the evidence for each particular way of doing it still has to be shown.
The Comparison That Makes the Point
| Population Medicine | Personalised Medicine |
|---|---|
| Diagnoses a condition based on symptom clusters | Investigates the mechanism driving the symptoms |
| Treats the diagnosis with the protocol that works for most people | Treats the identified mechanism in this specific person |
| Reference ranges derived from population distributions | Population ranges read alongside your history, trends over time and other results |
| Drug dosing standardised by weight/age | Dosing informed by test results, medicines and response |
| Dietary guidance based on population epidemiology | Dietary guidance based on individual metabolic response |
| Success measured by symptom management | Success measured by resolution of the underlying pattern |
| Accessible to everyone through public funding | Accessible privately, outside NHS infrastructure |
That last row is the one that makes people uncomfortable, and rightly so. Personalised medicine as currently delivered — through private functional medicine practice, precision oncology, pharmacogenomic testing — is expensive and therefore inequitable. This is a genuine problem. The answer to it, however, is not to pretend that the population-level system provides individual-level precision. It is to be honest about what each approach can and cannot deliver, and to work towards making individual-specific assessment more accessible over time.
Where Functional Medicine Gets It Wrong
The critique of conventional medicine as population-level and impersonal does not make functional medicine immune to its own version of the same problem. The supplement industry that sits adjacent to functional medicine — and sometimes claims to be part of it — applies the same one-size-fits-all logic in the opposite direction. Everyone needs collagen. Everyone needs high-dose vitamin D. Everyone should be taking probiotics. Everyone benefits from a greens powder.
This is population medicine with a wellness label. It is the functional medicine version of the same error — applying a generalised recommendation to an individual without individual-specific data. The clinical rationale for personalised medicine is not just that conventional medicine is too broad. It is that any recommendation made without individual data is, by definition, a guess. The recommendation may be directionally correct for the average person. It may be exactly wrong for the specific person.
The supplement that everyone in the wellness space is recommending this month may be contraindicated for someone with your specific gut microbiome, your specific genetic variants, your specific medication burden, or your specific metabolic type. Without testing, you cannot know. This is not a reason to take nothing. It is a reason to test before you take anything, and to take what the testing indicates rather than what the algorithm recommended.
Why This Matters Now More Than Before
The convergence of several technologies is making genuinely personalised medicine more accessible than at any previous point. Functional laboratory testing — stool analysis, hormone profiling, organic acid testing, comprehensive blood chemistry — is now available to individuals without a referral or a hospital appointment. The analytical tools to interpret the data — AI-assisted pattern recognition, clinical decision support — are improving rapidly. The practitioner networks to apply the interpretation are growing.
What is also growing is the awareness, particularly among people who have cycled through conventional medicine without resolution, that the 12-minute appointment and the population-level protocol are not the only options. This awareness is the market that functional medicine serves — and it is a market that will continue to grow as the gap between what the NHS can provide at scale and what individuals need for complex, multi-system presentations continues to widen.
The framing that positions this as "alternative" medicine does two things simultaneously: it protects the conventional system from the comparison, and it protects the wellness industry from the rigour that clinical accountability requires. The accurate framing is simpler. There is medicine that is designed for populations, and medicine that is designed for the individual. Both have their place. Neither is complete without the other. And the person sitting in front of a practitioner with years of unexplained symptoms deserves to know that both exist.
The Test, Don't Guess Principle Applied to Medicine Itself
The same principle that governs the TDG clinical approach applies to choosing a healthcare pathway. Do not guess which approach will work for you based on what worked for someone else, or what is trending in your social media feed, or what your GP had time to offer in a 12-minute appointment. Gather the data. Understand what the data shows about your specific biology. Choose the intervention that addresses what the data has identified.
This is not a rejection of conventional medicine. Acute care, emergency intervention, surgery, infectious disease management — conventional medicine excels at these, and no amount of functional testing changes that. The TDG approach is not a replacement for your GP. It is an investigation into the chronic, multi-system dysfunction that your GP's 12-minute appointment was not designed to investigate — and an argument that you deserve that investigation, conducted with rigour, interpreted against your individual biology, and translated into an intervention that was built for you rather than for the average of everyone like you.
Personalised medicine is not a fringe idea. It is the direction medicine has always been trying to go. The question is not whether it is valid. It is whether you are going to wait for the system to deliver it at scale, or whether you are going to seek it now.
The TDG Five-Test Programme.
Five integrated functional tests. 300+ markers. 500+ data points. A protocol built from your biology — not a population average. This is what personalised medicine looks like in practice.
Learn about the TDG Programme → Take the free gut symptom quiz